Urothelial Carcinoma
Conditions
Interventions
Observation group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients histopathologically diagnosed with urothelial carcinoma, including those with bladder cancer or renal pelvic carcinoma; 2.Able to provide intact tumor tissues and their adjacent microenvironmental tissues to meet the requirements of spatial multi-omics technical analysis; 3.The patient is able to understand and sign the informed consent form, and agrees to participate in the study and sample collection. 4.Adult patients aged 18 years and above; 5.Sample quality meets the requirements for subsequent high-throughput spatial multi-omics technical analysis (e.g., RNA quality and intact tissue preservation).
Exclusion criteria
Exclusion criteria: 1.Patients with a history of other malignant tumors (unless cured for more than 5 years); 2.Patients with urothelial carcinoma of rare or mixed histological subtypes (e.g., with squamous cell carcinoma or adenocarcinoma components); 3.Pregnant or lactating women; 4.Patients with severe cardiovascular, hepatic, or renal insufficiency, active infections, or other diseases that may significantly affect the study results; 5.Concurrent participation in other clinical trials that may interfere with the present study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Completeness of integrated multi-omics molecular signature map of urothelial carcinoma and identification of core biomarkers; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunotherapy response rate and biomarker correlation in PDO-CAR-NK co-culture system;Spatial distribution of key cell subsets in tumor microenvironment and analysis of interaction pathways; | — |
Countries
China
Contacts
Public ContactHuang Hang
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed